-
6 days ago | 
wsj.com | Brian Gormley
Western drugmakers, investors increasingly aim to acquire Chinese compoundsMay 29, 2025 6:00 am ET|WSJ ProU.S. venture capitalists are racing to tap in to China’s growing biotechnology prowess, a shift moving the industry into a more global market for the most promising new drug candidates. Several licensing pacts between Western and Chinese drugmakers have marked China’s emergence in biotech, a rise decades in the making.
-
2 weeks ago | 
wsj.com | Brian Gormley
The NYSE debut is the first major IPO for a venture-backed digital-health company since the pandemic-era boomMay 22, 2025 7:33 pm ET|WSJ ProShares of Hinge Health jumped on their first day of trading on the New York Stock Exchange, giving a much-needed win to a digital-health industry that’s been starved of initial public offerings.
-
1 month ago | 
venturecapital.createsend1.com | Brian Gormley
Good day. Startup Creyon Bio has formed a collaboration with drugmaker Eli Lilly that could be worth more than $1 billion, the companies say.
Creyon, whose investors include DCVC Bio and Lux Capital, has technology capable of designing oligonucleotides, or short nucleic-acid sequences, that could be used to treat a range of diseases.
-
1 month ago | 
createsend.com | Brian Gormley
Good day. Startup Creyon Bio has formed a collaboration with drugmaker Eli Lilly that could be worth more than $1 billion, the companies say.
Creyon, whose investors include DCVC Bio and Lux Capital, has technology capable of designing oligonucleotides, or short nucleic-acid sequences, that could be used to treat a range of diseases.
-
1 month ago | 
venturecapital.cmail19.com | Brian Gormley
Good day. Startup Creyon Bio has formed a collaboration with drugmaker Eli Lilly that could be worth more than $1 billion, the companies say.
Creyon, whose investors include DCVC Bio and Lux Capital, has technology capable of designing oligonucleotides, or short nucleic-acid sequences, that could be used to treat a range of diseases.
-
1 month ago | 
wsj.com | Brian Gormley
Dr. Kate Knobil joins the biotech as it looks to combat a viral infection that can be dangerous to patients with the lung disease COPDMay 1, 2025 6:00 am ET|WSJ ProAltesa BioSciences has hired a top pharmaceutical executive to help develop a drug for a respiratory infection that is particularly serious for people with chronic obstructive pulmonary disease.
-
1 month ago | 
createsend.com | Brian Gormley
Good day. Knownwell,a Boston-based provider of primary-care and metabolic-health services to people who are overweight or obese, is expanding in the U.S. as it navigates insurance challenges in various geographic markets.
Knownwell, which says it offers comprehensive, non-stigmatizing care, raised seed financing in 2022 and the following year opened its first clinic in the Needham suburb of Boston.
-
1 month ago | 
createsend.com | Brian Gormley
Good day. Biotechnology company Glycomine is trying to create the first approved therapy for a rare and potentially life-threatening genetic disease that causes symptoms such as ataxia, or loss of muscle coordination.
The San Carlos, Calif.-based company recently raised a $115 million Series C financing to take aim at the disease, known as PMM2-CDG.
-
1 month ago | 
createsend.com | Brian Gormley
Good day. The global trade war has jolted financing markets, forcing many startups to consider alternatives to venture capital and initial public offerings. Haim Zaltzman, global vice chair of the emerging companies and growth practice of law firm Latham & Watkins, has been advising entrepreneurs as they navigate the turbulence. We spoke about financing alternatives with Zaltzman, whose practice includes work with biotech and medical-device startups, and venture and debt investors in these sectors.
-
1 month ago | 
createsend.com | Brian Gormley
Good day. Digital-health startups can capitalize on uncertain times to make big leaps if they are willing to take risks on creative business models and strategies, according to an analysis by Rock Health.
The conventional playbook of raising rounds of venture capital until a company is acquired or goes public isn’t always the best approach for startups innovating in areas such as healthcare artificial intelligence or virtual care.
